最新临床研究显示，默沙东旗下PD-1抑制剂Keytruda（帕博利珠单抗）联合紫杉醇（含或不含贝伐珠单抗）治疗方案，在治疗铂类药物耐药复发性卵巢癌患者时，其关键次要终点——总生存期（OS）取得显著改善，效果优于单独使用紫杉醇（含或不含贝伐珠单抗）的对照组。
这一突破性数据为晚期卵巢癌治疗提供了新的方向。研究结果表明，免疫联合疗法在延长患者生存时间方面展现出明确优势，特别是针对既往铂类药物治疗失效的难治性患者群体。该治疗方案的成功验证了免疫检查点抑制剂在妇科恶性肿瘤治疗领域的应用潜力。
值得注意的是，总生存期的改善作为评价抗癌疗法临床价值的金标准，此次突破性进展或将重塑卵巢癌二线治疗格局。随着后续数据的持续披露，这一联合疗法有望为更多面临治疗困境的卵巢癌患者带来新生机。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.